Sartorius rises after H1 beat, guidance confirmed

Sartorius AG

23/07/2026 07:48

** Shares in German biopharma group Sartorius SATG.DE rise 4% in early Frankfurt trade after H1 results show continued growth and higher profitability, with FY guidance confirmed
** Company H1 operational sales revenue, excluding tariff compensation to customers, grew 7.7% in constant currencies to €1.81 ($2.07) billion 
** It says recurring consumables remained the main growth driver, while bioprocess business and lab instruments stabilised further and returned to slight growth
** H1 underlying EBITDA rose 3.9% to 548 mln euros, with margin up 50 bps to 30.3%, helped by higher volumes and economies of scale
** Jefferies says reiterated guidance should reassure the market after recent share price volatility following Danaher's results
** Broker says growth continues to be consumables-driven, adding investors will focus on the sustainability of strong Asia-Pacific growth and visibility on orders, particularly in equipment
** Up to the previous session's close, shares were down 6.1%​ YTD


($1 = 0.8749 euros)

 (Reporting by Basile Day)
 ((Basile.Day@thomsonreuters.com))